GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » EBIT

Zimmer Biomet Holdings (Zimmer Biomet Holdings) EBIT : $1,269 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Zimmer Biomet Holdings EBIT?

Zimmer Biomet Holdings's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $335 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $1,269 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zimmer Biomet Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was 12.39%. Zimmer Biomet Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 30.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zimmer Biomet Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.21%.


Zimmer Biomet Holdings EBIT Historical Data

The historical data trend for Zimmer Biomet Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings EBIT Chart

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,132.70 106.90 707.40 568.30 1,268.50

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.20 335.00 328.40 270.30 334.80

Competitive Comparison of Zimmer Biomet Holdings's EBIT

For the Medical Devices subindustry, Zimmer Biomet Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's EV-to-EBIT falls into.



Zimmer Biomet Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,269 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zimmer Biomet Holdings  (NYSE:ZBH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zimmer Biomet Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1683.2 * ( 1 - -47.52% )/( (20508.4 + 19564.5)/ 2 )
=2483.05664/20036.45
=12.39 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Zimmer Biomet Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1339.2/( ( (2032.2 + max(2363.4, 0)) + (2060.4 + max(2236.3, 0)) )/ 2 )
=1339.2/( ( 4395.6 + 4296.7 )/ 2 )
=1339.2/4346.15
=30.81 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1340.7 + 2323.3 + 415.9) - (416.8 + 0 + 1299.7)
=2363.4

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1442.4 + 2385.2 + 366.1) - (1516.6 + 0 + 440.8)
=2236.3

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zimmer Biomet Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=1268.5/30100.809
=4.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zimmer Biomet Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Executives
Syed A. Jafry director 345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli director C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley director
Robert Hagemann director 3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson director 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard director 711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps officer: Assoc. Gen. Counsel, Corp. Sec C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van officer: Pres, Europe, M. East & Africa 345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato officer: VP, Controller & CAO C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi officer: President, Asia Pacific 345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler officer: SVP and CHRO 345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson officer: SVP & CSO 345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson director, officer: President and CEO ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau officer: Group President 345 E. MAIN STREET, WARSAW IN 46580

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Headlines